Physician profile
Yu Yu
NPI 1245281278
$3,324.42
in general payments reported to CMS, 2019-2025
18 companies · $81.84 in 2025
The $81.84 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $152 · 2021: $45.70 · 2022: $287 · 2023: $532 · 2024: $423 · 2025: $81.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006 · Education: $30.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.75 |
| Education | $30.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $1,280.63 | 2019 | |
| Abbvie INC. | $364.24 | 2019-2025 | |
| Kyowa Kirin, INC. | $285.52 | 2023-2025 | Crysvita |
| Insulet Corporation | $263.56 | 2022-2023 | Omnipod |
| Ascendis Pharma Endocrinology INC | $167.65 | 2024 | |
| Biomarin Pharmaceutical INC. | $144.16 | 2019-2022 | |
| Beta Bionics, INC. | $124.18 | 2023 | Ilet Bionic Pancreas |
| Lilly USA, LLC | $122.80 | 2024 | Zepbound, Mounjaro |
| Rhythm Pharmaceuticals, INC. | $114.91 | 2023 | Imcivree |
| Ultragenyx Pharmaceutical INC. | $104.24 | 2019 | |
| Novo Nordisk INC | $96.81 | 2019 | |
| Bard Peripheral Vascular, INC. | $81.85 | 2020 | |
| Pfizer INC. | $57.70 | 2019 | |
| Neurocrine Biosciences, INC. | $33.73 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $22.89 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.56 | 2021 | |
| Endo Pharmaceuticals INC. | $19.58 | 2019 | |
| Sandoz INC. | $17.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.